Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published March 1, 2021 | Supplemental Material + Submitted + Published
Journal Article Open

Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder

Abstract

Background: Autism spectrum disorder (ASD) is a neurodevelopmental condition with hallmark behavioral manifestations including impaired social communication and restricted repetitive behavior. In addition, many affected individuals display metabolic imbalances, immune dysregulation, gastrointestinal dysfunction, and altered gut microbiome compositions. Methods: We sought to better understand nonbehavioral features of ASD by determining molecular signatures in peripheral tissues through mass spectrometry methods (ultrahigh performance liquid chromatography–tandem mass spectrometry) with broad panels of identified metabolites. Herein, we compared the global metabolome of 231 plasma and 97 fecal samples from a large cohort of children with ASD and typically developing control children. Results: Differences in amino acid, lipid, and xenobiotic metabolism distinguished ASD and typically developing samples. Our results implicated oxidative stress and mitochondrial dysfunction, hormone level elevations, lipid profile changes, and altered levels of phenolic microbial metabolites. We also revealed correlations between specific metabolite profiles and clinical behavior scores. Furthermore, a summary of metabolites modestly associated with gastrointestinal dysfunction in ASD is provided, and a pilot study of metabolites that can be transferred via fecal microbial transplant into mice is identified. Conclusions: These findings support a connection between metabolism, gastrointestinal physiology, and complex behavioral traits and may advance discovery and development of molecular biomarkers for ASD.

Additional Information

© 2020 Society of Biological Psychiatry. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Received 15 April 2020, Revised 30 September 2020, Accepted 30 September 2020, Available online 10 October 2020. This work was supported by Autism Speaks (Grant No. 7567 [to PA, AF, and SKM]), the Johnson Foundation (to PA), the Brain Foundation (to PA), Genome, Environment, Microbiome, and Metabolome in Autism (Grant No. 825033 [to AF]), Axial Biotherapeutics (to SKM), and the National Institutes of Health (Grant No. HD090214 [to PA] and Grant No. MH100556 [to SKM]). We thank the MIND Institute study staff, and the dedication and commitment of the families who took part in these studies are gratefully acknowledged. ASC, DHD, and SKM have financial interest in Axial Biotherapeutics. AF has financial interest in Alba Therapeutics. GMP and MCC are employed by Axial Biotherapeutics. All other authors report no biomedical financial interests or potential conflicts of interest.

Attached Files

Published - 1-s2.0-S0006322320319855-main.pdf

Submitted - 2020.05.17.098806v1.full.pdf

Supplemental Material - 1-s2.0-S0006322320319855-mmc1.pdf

Supplemental Material - 1-s2.0-S0006322320319855-mmc2.xlsx

Supplemental Material - 1-s2.0-S0006322320319855-mmc3.xlsx

Supplemental Material - 1-s2.0-S0006322320319855-mmc4.xlsx

Files

1-s2.0-S0006322320319855-main.pdf
Files (21.7 MB)
Name Size Download all
md5:d21dd5710e47292e2bfd8c4ed0e49cd1
723.3 kB Preview Download
md5:ad1e71c264cddcf5edd1a45365a12498
2.8 MB Preview Download
md5:e38c986c073c9e7bf84153cc63ed5b29
12.8 kB Download
md5:1a5260c48062c2d222635662d1f70222
6.3 MB Download
md5:434a7a13edfa5905384b8976c1a69e7a
8.6 MB Download
md5:d0bc4596f10078e1eeeccda229f1939c
3.4 MB Preview Download

Additional details

Created:
August 22, 2023
Modified:
December 22, 2023